News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

5 Best Biotech Stocks to Buy in the 2nd Half of 2017



7/12/2017 6:00:14 AM

5 Best Biotech Stocks to Buy in the 2nd Half of 2017 July 12, 2017
By Mark Terry, BioSpace.com Breaking News Staff

Biotech stocks had a tough time of it in 2016, likely due to the heated political rhetoric over drug pricing during the U.S. presidential election. Although that hasn’t gone away completely, the political debate has died down, and it seems unlikely that Congress or the Trump White House are going to be able to pull off any dramatic legislative changes in drug pricing any time soon. Meanwhile, 2017 is a booming year for biotech stocks.


The SPDR S&P Biotech ETF has been averaging a monthly gain of 5.4 percent in July, the best rate historically. With that in mind, Zacks took a look at five hot biotech stocks to consider for the second half of the year.

1. Vertex Pharmaceuticals

Headquartered in Boston, Mass., Vertex (VRTX) focuses on rare diseases. Its big product is Orkambi for cystic fibrosis. It is currently working on a triple-pill combination for cystic fibrosis, and it’s possible the combo treatment will launch in 2020.

Zacks notes that the company’s expected growth rate for this year is a startling 492.2 percent.

Vertex shares are currently trading for $131.40.

2. Alimera Sciences

Based in Alpharetta, Georgia, Alimera (ALIM) focuses—no pun intended—on diseases of the eye. It announced on Monday that it secured the rights to pursue posterior uveitis, a secondary indication for its drug Iluvien, in Europe, the Middle East and Africa.

Its projected growth rate for this year is 73.8 percent.

Alimera shares are currently trading for $1.50.

3. Enzo Biochem

Located in Farmingdale, N.Y., Enzo (ENZ) is a life sciences and biotech company that also develops research tools, diagnostics and therapeutics, and offers clinical diagnostic reference laboratory services. It has three wholly owned subsidiaries, Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs.

At its third-quarter financial report on June 8, Enzo reported total revenues of $27.1 for the quarter, a 2 percent increase from the same period in 2016. The company reported total revenues for the nine-month period of $79.6 million, up from $76.2 million in the same period the year before.

Zacks indicates Enzo has an expected growth rate this year of 65 percent.

Enzo shares are currently trading for $11.18.
  Related Jobs  
  Principal Scientist – Celgene
  Scientist, Quality Control, Seattle Genetics
  Respiratory Clinical Science Liaison - Astra
  Scientist I, Translational Science - MedImmune
  Research Associate, Biology - Tenaya Therapeutics
  Sr. Automation Engineer - Regeneron
  View More Jobs


4. Sarepta Therapeutics

Headquartered in Cambridge, Mass., Sarepta (SRPT) is best known for Exondys 51, its controversial drug for Duchenne muscular dystrophy (DMD), which was approved by the U.S. Food and Drug Administration (FDA) last fall. On June 29, the company named Douglas Ingram as its new president and chief executive officer, replacing Edward Kaye, who led the company through the DMD approval process.

Zacks writes, “Sarepta Therapeutics’ expected growth rate for the current year is 47.5 percent, more than the Medical – Biomedical and Genetics industry’s estimated gain of 5.5 percent.”

Sarepta shares are currently trading for $34.89.

5. Exact Sciences

Based in Madison, Wisconsin, Exact (EXAS) manufactures and markets Cologuard, the first and only FDA approved stool DNA noninvasive colorectal cancer screening test. There probably isn’t a person on the planet who’s ever had a standard colonoscopy who wouldn’t prefer to take the non-invasive Cologuard test instead. Physicians still view colonoscopy as the gold standard, largely due to false positives and false negatives with Cologuard and the fact that for both, the colonoscopy is the reflex test anyway. Approved by the FDA, it is also covered by Medicare and an increasing number of insurers.

The company’s expected growth rate for this year is 18 percent.

Exact Sciences shares are currently trading for $38.38.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES